XEN45 implant effective for long-term glaucoma management

The XEN45 implant is both effective and safe for long-term management of open-angle glaucoma, significantly lowering intraocular pressure (IOP) and reducing the need for ocular-hypotensive medications, whether used alone or in combination with phacoemulsification, according to a study.

This retrospective study evaluated 158 eyes of patients with open-angle glaucoma (OAG) for a median follow-up time of 28.5 months. Researchers defined surgical success as a ≥ 20% decrease in IOP from baseline, with an IOP value between 6 mm Hg and 13 mm Hg. Success was classified as either complete (without additional antiglaucoma medications) or qualified (with additional medications).

Results showed a significant reduction in IOP from a preoperative average of 19.4 mm Hg to a postoperative average of 12.4 mm Hg. The implant used alone group saw a drop from 21.3 mm Hg to 12.0 mm Hg, while the implant in combination with phacoemulsification group experienced a decrease from 18.8 mm Hg to 12.5 mm Hg.

The study also reported a significant reduction in the number of ocular-hypotensive medications, from 3.4 to 0.9 on average across the study population.

Out of the total eyes studied, 84 (53.2%) achieved surgical success, with 49 (58.3%) classified as complete success. In addition, 81 eyes (51.3%) required needling, and 15 eyes (9.5%) underwent additional surgical procedures. Only 1 case of endophthalmitis (0.6%) was reported.

Reference
Carassa RG, Corsini G, Triolo G. Long-term effectiveness and safety of XEN45 in open-angle glaucoma patients. Int Ophthalmol. 2024;44(1):310. doi: 10.1007/s10792-024-03234-2. PMID: 38960998.